Inogen’s 2024 annual report flagged a return to growth, led by a sharp rebound in its business-to-business channel.
Direct-to-consumer sales remained under pressure following salesforce reductions; the rental channel also weakened as patients shifted toward private insurance.
Collaboration with Yuwell Medical positioned the company to enter China while adding a stationary oxygen concentrator to its portfolio.
FDA 510(k) clearance for the Simeox airway clearance device in December set up a US commercialization push, with reimbursement work starting in Q1 2025.
Product updates included the Rove 4 portable oxygen concentrator launch in October, supported by new features for the Inogen Connect app.
INGN•
